Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
e-Therapeutics plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'e-Therapeutics plc - Product Pipeline Review - 2014', provides an overview of the e-Therapeutics plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of e-Therapeutics plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of e-Therapeutics plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of e-Therapeutics plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the e-Therapeutics plc's pipeline products Reasons to buy - Evaluate e-Therapeutics plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of e-Therapeutics plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the e-Therapeutics plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of e-Therapeutics plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of e-Therapeutics plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of e-Therapeutics plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 e-Therapeutics plc Snapshot 5 e-Therapeutics plc Overview 5 Key Information 5 Key Facts 5 e-Therapeutics plc - Research and Development Overview 6 Key Therapeutic Areas 6 e-Therapeutics plc - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 e-Therapeutics plc - Pipeline Products Glance 10 e-Therapeutics plc - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Phase I Products/Combination Treatment Modalities 11 e-Therapeutics plc - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 e-Therapeutics plc - Drug Profiles 14 tramadol 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 dexanabinol 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 ETS-2123 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ETS-6218 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ETX-6201 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ETX-6765 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 CNS NP Programmes 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ETX-6771 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 ETX-6991 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Oncology NP Programmes 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 e-Therapeutics plc - Pipeline Analysis 26 e-Therapeutics plc - Pipeline Products by Target 26 e-Therapeutics plc - Pipeline Products by Route of Administration 27 e-Therapeutics plc - Pipeline Products by Molecule Type 28 e-Therapeutics plc - Pipeline Products by Mechanism of Action 29 e-Therapeutics plc - Recent Pipeline Updates 30 e-Therapeutics plc - Dormant Projects 33 e-Therapeutics plc - Discontinued Pipeline Products 34 Discontinued Pipeline Product Profiles 34 (disulfiram + miconazole) 34 (nisin + miconazole) 34 e-Therapeutics plc - Company Statement 35 e-Therapeutics plc - Locations And Subsidiaries 39 Head Office 39 Other Locations & Subsidiaries 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 41 Disclaimer 41
List of Tables e-Therapeutics plc, Key Information 5 e-Therapeutics plc, Key Facts 5 e-Therapeutics plc - Pipeline by Indication, 2014 7 e-Therapeutics plc - Pipeline by Stage of Development, 2014 8 e-Therapeutics plc - Monotherapy Products in Pipeline, 2014 9 e-Therapeutics plc - Phase II, 2014 10 e-Therapeutics plc - Phase I, 2014 11 e-Therapeutics plc - Preclinical, 2014 12 e-Therapeutics plc - Discovery, 2014 13 e-Therapeutics plc - Pipeline by Target, 2014 26 e-Therapeutics plc - Pipeline by Route of Administration, 2014 27 e-Therapeutics plc - Pipeline by Molecule Type, 2014 28 e-Therapeutics plc - Pipeline Products by Mechanism of Action, 2014 29 e-Therapeutics plc - Recent Pipeline Updates, 2014 30 e-Therapeutics plc - Dormant Developmental Projects,2014 33 e-Therapeutics plc - Discontinued Pipeline Products, 2014 34 e-Therapeutics plc, Subsidiaries 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.